New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Abstract

A new clone of Newcastle disease virus which is interferon insensitive and has an ICPI between 1.2 and 2.0 and which may be used in the treatment of cancer and other diseases.

1 . A purified Newcastle Disease Virus clone which is interferon insensitive and has an ICPI between 1.2 and 2.0. 
     
     
         2 . A purified Newcastle Disease Virus clone according to  claim 1  which is interferon insensitive and has an ICPI between 1.2 and 1.5. 
     
     
         3 . A purified Newcastle Disease Virus clone according to  claim 1  comprising the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         4 . A method of treating human cancer patients comprising administration to said patients of a therapeutically effective amount of the purified Newcastle Disease Virus clone of  claim 1 . 
     
     
         5 . A method of treating human cancer patients comprising administration to said patients of a therapeutically effective amount of the purified Newcastle Disease Virus clone of  claim 3 . 
     
     
         6 . A method according to  claim 4  or  5  in which virus treatment is combined with chemotherapy, radiotherapy, immunotherapy or surgery. 
     
     
         7 . A method for treating interferon sensitive neoplastic conditions and non-neoplastic interferon sensitive autoimmune and viral conditions in human patients comprising an administration to said patients of a therapeutically effective amount of the purified Newcastle Disease Virus clone of  claim 1 . 
     
     
         8 . A method according to  claim 7  in which the purified Newcastle Disease virus clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         9 . A method to reduce pain perception in a cancer patient comprising application to said cancer patient of a Newcastle Disease virus clone which is interferon insensitive and has an ICPI between 1.2 and 2.0. 
     
     
         10 . A method according to  claim 9  in which the purified Newcastle Disease virus clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         11 . A method to reduce side effects of chemotherapy in a cancer patient treated with chemotherapeutic agents comprising application to said patient of a Newcastle Disease virus clone which is interferon insensitive and has an ICPI between 1.2 and 2.0 before, together, or after the chemotherapeutic agent. 
     
     
         12 . A method according to  claim 11  in which the purified Newcastle Disease virus clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         13 . A method to reduce radionecrosis in a cancer patient treated with radiation comprising the application to said patient of a Newcastle Disease virus clone which is interferon insensitive and has an ICPI between 1.2 and 2.0 before, together, or after radiotherapy. 
     
     
         14 . A method according to  claim 13  in which the purified Newcastle Disease virus clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         15 . A method to reduce side effects including acute or chronic sequelae of radiotherapy in a cancer patient treated with radiation comprising the application to said patient of a Newcastle Disease virus clone which is interferon insensitive and has an ICPI between 1.2 and 2.0 before, together, or after radiotherapy. 
     
     
         16 . A method according to  claim 15  in which the purified Newcastle Disease clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         17 . A method to increase the quality of life in a cancer patient comprising the application to said patient of a Newcastle Disease virus clone which is interferon insensitive and has an ICPI between 1.2 and 2.0. 
     
     
         18 . A method according to  claim 17  in which the purified Newcastle Disease virus clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         19 . A pharmaceutical composition for treating cancer comprising as an active ingredient a Newcastle Disease virus clone according to  claim 1  together with physiologically acceptable additives. 
     
     
         20 . A pharmaceutical composition according to  claim 19  in which the purified Newcastle Disease virus clone comprises the DNA nucleotide sequence of SEQ ID NO: 2. 
     
     
         21 . A Newcastle Disease Virus according to  claim 1  which is freeze-dried. 
     
     
         22 . A Newcastle Disease Virus according to  claim 2  which is freeze-dried. 
     
     
         23 . A Newcastle Disease Virus according to  claim 3  which is freeze-dried. 
     
     
         24 . A method, according to  claim 7 , wherein said interferon sensitive neoplastic conditions are selected from the group consisting of Melanoma, non-Hodgkins Lymphomas, Leukemias, Breast cancer, Bladder Carcinoma, Renal cell carcinoma, Head and Neck cancer, Carcinoid tumors, Bile Duct cancers, Pancreatic cancer, Multiple Myeloma and Kaposi Sarcoma. 
     
     
         25 . A method, according to  claim 7 , wherein said non-neoplastic interferon sensitive autoimmune and viral conditions are selected from the group consisting of Multiple sclerosis, Condylomata acuminata, Hepatitis, Herpes, Rheumatic Arthritis, Behcet's Disease, Idiopathic Pulmonary Disease, Aphthous stomatitis, Severe Malignant Osteoporosis, cervix cancer and SARS. 
     
     
         26 . A purified Newcastle Disease Virus clone comprising the DNA nucleotide sequence of SEQ ID NO: 2.